Research Paper Volume 16, Issue 18 pp 12525—12542
Revealing a cancer-associated fibroblast-based risk signature for pancreatic adenocarcinoma through single-cell and bulk RNA-seq analysis
Figure 6. Risk signature response to immunotherapy in IMvigor210 and GSE78220 cohorts. (A) Prognostic differences among IMvigor210 cohort subgroups based on the risk score. (B) Variations in risk scores within IMvigor210 cohort responses to immunotherapy. (C) Distribution of immunotherapy responses among risk score groups in the IMvigor210 cohort. (D) Prognostic differences among subgroups of early-stage patients in the IMvigor210 cohort based on the risk score. (E) Prognostic differences among subgroups of advanced-stage patients in the IMvigor210 cohort based on the risk score. (F) Prognostic differences among subgroups of the GSE78220 cohort based on the risk score. (G) Variations in risk scores among GSE78220 cohort responses to immunotherapy. (H) Distribution of immunotherapy responses among risk score groups in the GSE78220 cohort.